BI2536

Protein target name:

PLK1, PLK2, PLK3

Mechanism of action:

ATP-competitive inhibitor

Recommended Concentration for use in cells:

N/A

Probe Availability

Cayman (755038-02-9)

MedChem Express (755038-02-9)

Probe Information

Target and Probe Information

Target Details

Target class:

Protein kinase

Subclass:

Other

HUGO symbol:

PLK1 PLK2 PLK3

Entrez gene ID:

5347 10769 1263

Probe Details

Chemical Probes Portal ID:

CPP88

PubChem CID:

11364421

ChEMBL ID:

CHEMBL513909

SMILES string:

CC[C@@H]1C(=O)N(C2=CN=C(N=C2N1C3CCCC3)NC4=C(C=C(C=C4)C(=O)NC5CCN(CC5)C)OC)C

InChi Key:

XQVVPGYIWAGRNI-JOCHJYFZSA-N

PAINs evaluation:

PAINs free

Validation in Cells and Model Organisms

In vitro validation

On target activity

Potency:

IC50

PLK1 0.83 nM, PLK2 3.5 nM, PLK3 9 nM

Off target activity

Potency assay (off target):

>1,000-fold selective for PLK proteins over 63 additional protein kinases

In cell validation

On target activity in cells

Potency assay (cells):

In HeLa cells, BI2536 dose-dependently inhibited substrate phosphorylation, caused G2/M arrest and led to PARP p85 fragment formation, with activity saturating between 10-100 nM

Target engagement assay (cells):

Indirect: inhibition of substrate phosphorylation

Primary Reference

Reference (doi):

doi:10.1016/j.cub.2006.12.037

Reference (PMID):

17291758

SAB Rating

Rating for use in Cells

3 review(s)

Rating for use in Model Organisms

3 review(s)

SAB Members

SAB Comments

BI-2356 has been subject to kinome profiling (doi:10.1038/nbt.1990). Although it is active against >20 kinases at 1 uM, it is potent and selective for PLK1, PLK2, and to a lesser extent PLK3 at very low nM doses. CAMKK1/2 and RPS6KA4 (Kin.Dom.2-C-terminal) would be off-targets in the ~20 nM and 12 nM range, respectively.

BI 2536 given i.v. once or twice per week is highly efficacious in diverse xenograft models with acceptable tolerability by inhibiting cell proliferation through a mitotic arrest, and subsequently induction of tumor-cell death. Administration of BI 2536 at 50 mg/kg once or twice per week significantly inhibits growth of HCT 116 xenografts with T/C of 15% and 0.3%, respectively. BI 2536 treatment twice-weekly also leads to excellent tumor-growth in BxPC-3 and A549 models with T/C of 5% and 14%, respectively.

BI 2536 blocks the activities of PLK2 and PLK3 with IC50s of 3.5 nM and 9.0 nM, respectively. In HeLa cells, BI 2536 treatment ranging from 10-100 nM leads to the blocking of the recruitment of γ-tubulin and phosphorylation of APC6 at mitotic centrosomes, inhibition of cohesin release from chromosome arms, induction of monopolar spindles, as well as a range of other mitotic processes that are known to depend on PLK1. BI 2536 treatment leads to HeLa cell arrest in G2/M, subsequently a sub-G1 DNA peak indicative of DNA breakdown and apoptosis, and accumulated cleaved PARP p85 fragments in a concentration-dependent manner. BI 2536 inhibits the growth of a panel of 32 human cancer cell lines with EC50s of 2-25 nM, while blocking the proliferation of exponentially growing hTERT-RPE1, human umbilical vein endothelial cells (HUVECs), and normal rat kidney (NRK) cells with EC50s of 12-31 nM. PLK1 inhibition by BI 2536 reduces the growth and viability of anaplastic thyroid carcinoma (ATC) cells such as CAL62, OCUT-1, SW1736, 8505C, and ACT-1 with EC50 values of 1.4-5.6 nM.

BI2536 is a potent inhibitor of the PLK kinase family (PLK1/2/3 IC50 0.83/3.5/9.0 nM). Its selectivity was excellent in a protein kinase panel of modest size (63 other kinases). PLK4 was not a member of that panel. BI2536 is cell-permeable, causing HeLa cell-cycle block in G2 or mitosis at 10-50 nM and inhibiting a range of other cancer cell proliferation at 1-100 nM EC50. It was effective in a mouse xenograft model intravenously dosed (40-50 mg/kg weekly or bi-weekly). This compound is not a pure PLK chemical probe; it is also a potent inhibitor of the BET family bromodomains (BRD4-BD1 IC50 25 nM by AlphaScreen, Kd 37 nM by ITC, IC50 100 nM vs BRD4 in a FRAP cellular assay) and has a polypharmacological profile (doi:10.1021/cb500072z, doi:10.1038/nchembio.1471) For that reason, I would not choose this compound as a selective probe for the PLK family.

BI2536 is a reasonably selective PLK inhibitor (PLK1/2/3) but BI2536 also targets BET bromodomains (DOI: 10.1021/acsmedchemlett.5b00084). Despite being a PLK1 inhibitor that induces all the hallmarks of PLK1 inhibition, any observed cellular phenotypes should be interpreted with caution. BI2536 is considered a compound with polypharmacological activity; it has been superseded by volasertib (BI6727).

BI2536

Probe Availability

Probe Information

Target Details

Probe Details

In vitro validation

In cell validation

Primary Reference

Supporting Organizations

Interested in supporting the portal?

Search form

BI2536

Probe Availability

Probe Information

Target Details

Probe Details

In vitro validation

In cell validation

Primary Reference

Supporting Organizations

Interested in supporting the portal?